Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Blog | April 28, 2022

Crafting a Comprehensive Trade Secret Strategy

Blog | April 28, 2022

Legal Alert: WIPO Standard ST.26 is coming into force before the European Patent Office on July 1, 2022

Blog | April 26, 2022

Marking and Pre-Suit Damages: What Happens when a Failure to Mark Is Followed by a Period of Compliance with the Marking Statute?

Article | April 19, 2022

Patent Licensing

Blog | April 05, 2022

ITC Monthly Wrap-Up: March 2022

Blog | April 04, 2022

European Patent Office Updates Procedure for Issuing Grant Certificates

Blog | April 04, 2022

Texas Patent Litigation Monthly Wrap-Up: March 2022

Article | April 01, 2022

USPTO Director Review Is A Rare Remedy After Arthrex

Article | March 31, 2022

Regenxbio v. Sarepta: Make Sure You're Safely Within the Safe Harbor Before Using a 'Research Tool'

Article | March 14, 2022

Stays Pending IPR In Del. District Courts Are Here To Stay

Article | March 11, 2022

A Slow Year for PTAB Precedential Decisions

Blog | February 25, 2022

European Patent Office to Increase Fees on April 1, 2022